Skip to main content

Table 1 Drug toxicity enhancement factors (EF's) obtained in human tumour cell lines when cells were blocked in G2 with irradiation and then subjected to Pentoxifylline and a TC: 05 dose of a cytotoxic drug. Data adapted from [6]

From: Inhibition of homologous recombination repair with Pentoxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation

Cell line a   Drug EF's
4197 p53 wt b D, M, CP 1.3 3.0 2.6
4451 p53 mut b D, M, CP 2.3 8.6 52
Be11 p53 wtb D, M, CP 1.4 2.3 1.2
MeWo p53 mut b D, M, CP 2.8 85 74
DU 145 p53 mut c V, E, CP 4.8 1.5 4.1
BM1604 p53 mut c V, E, CP 2.6 1.0 4.5
LNCaP p53 wt c V, E, CP 1.4 1.5 1.6
  1. a) 4197 and 4451 are human squamous carcinoma cell lines. Be-11 and MeWo are human melanoma cell lines. The DU-145 prostatic tumour cell line was established from a metastatic central nervous system lesion. The BM 1604 cell was established from a radical prostatectomy biopsy. The LnCaP cell line was established from a supraclavicular lymph node metatstasis of a human prostate adenocarcinoma.
  2. D: Daunorubicin; E: Etoposide; M: Melphalan; V: Vinblastine; CP: cisplatin based on clonogenic SF 7 (survival fraction at 7 Gy) and dye staining data b) Binder et al. [4] ; c) Serafin et al. [40]